Press Release

NEW YORK and LONDON, January 4th, 2017 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, has expanded its …

[Read more...] about Akari Therapeutics Expands Clinical and Regulatory Teams with Industry Veterans

NEW YORK and LONDON, January 3rd, 2017 Phase II trial in eculizumab resistant PNH expected to expand into US Akari Therapeutics (NASDAQ: AKTX), an …

[Read more...] about Akari Therapeutics Announces FDA Allowance of IND for Clinical Development of Coversin in PNH

NEW YORK and LONDON, December 5th, 2016 - Phase Ib cohorts demonstrate dose effect and additional support for once daily dosing- -PAS-Coversin pre-clinical …

[Read more...] about Akari Therapeutics Announces Corporate Update with New Positive Clinical Data and a New Pipeline of Tick Derived and Engineered Proteins

NEW YORK and LONDON, November 11th, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today …

[Read more...] about Akari Therapeutics to Attend Upcoming Investor Conferences In November

- Akari will host an analyst and investor symposium on Saturday, Dec 3 - NEW YORK and LONDON, November 3rd, 2016 Akari Therapeutics (NASDAQ: AKTX), an …

[Read more...] about Akari Therapeutics to Present Abstract on Potential Once Weekly PAS-Coversin at the 58th Annual Meeting of the American Society of Hematology